Keyphrases
BNT162b2 Vaccine
100%
Adverse Events
100%
Antibody Titer
100%
Healthcare Workers
100%
Adverse Drug Reaction
100%
Receptor-binding Domain
37%
Antireceptor
37%
Reactogenicity
37%
First Dose
25%
Logistic Regression Analysis
25%
Antibody Level
25%
Second Dose
25%
Young Age
12%
Vaccination
12%
COVID-19
12%
SARS-CoV-2 Infection
12%
Active Surveillance
12%
Vaccine Immunogenicity
12%
Text Messaging
12%
Highly Effective
12%
Young Female
12%
Immunogenicity
12%
Female Gender
12%
BNT162b2
12%
Vaccine Dose
12%
IgG Titer
12%
IgG Levels
12%
Drug Antibodies
12%
Spearman Correlation
12%
Virus Neutralization
12%
Post-vaccination Antibodies
12%
Medicine and Dentistry
Adverse Event
100%
Messenger RNA
100%
COVID-19 Vaccine
100%
Adverse Drug Reaction
100%
Reactogenicity
50%
Receptor Binding
37%
Logistic Regression Analysis
12%
Infection
12%
COVID-19
12%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Study Participant
12%
Multivariate Logistic Regression Analysis
12%
Health Care
12%
Neutralization
12%
Immunogenicity
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Messenger RNA
100%
COVID-19 Vaccine
100%
Adverse Drug Reaction
100%
Receptor
37%
Infection
12%
SARS Coronavirus
12%
Immunogenicity
12%
Biochemistry, Genetics and Molecular Biology
Messenger RNA
100%
Titer
100%
Binding Domain
100%
Receptor Binding
100%
SARS Coronavirus
33%
Immunogenicity
33%
Immunology and Microbiology
COVID-19
100%
Antibody Titer
100%
Drug Hypersensitivity
100%
Receptor Binding
37%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Titer
12%
Immunogenicity
12%
Neutralization
12%
Drug Antibody
12%